DK16487A - Vacciner til oral indgift - Google Patents

Vacciner til oral indgift

Info

Publication number
DK16487A
DK16487A DK016487A DK16487A DK16487A DK 16487 A DK16487 A DK 16487A DK 016487 A DK016487 A DK 016487A DK 16487 A DK16487 A DK 16487A DK 16487 A DK16487 A DK 16487A
Authority
DK
Denmark
Prior art keywords
complex
immunogen
medicaments
well
cellular
Prior art date
Application number
DK016487A
Other languages
English (en)
Other versions
DK16487D0 (da
DK171846B1 (da
Inventor
Gregory John Russell-Jones
Henry James De Aizpurua
Peter Howe
Keith Norman Rand
Original Assignee
Biotech Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25642944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK16487(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotech Australia Pty Ltd filed Critical Biotech Australia Pty Ltd
Publication of DK16487D0 publication Critical patent/DK16487D0/da
Publication of DK16487A publication Critical patent/DK16487A/da
Application granted granted Critical
Publication of DK171846B1 publication Critical patent/DK171846B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
DK016487A 1985-05-15 1987-01-14 Et kompleks, en fremgangsmåde til fremstilling af dette kompleks, en transformant vært, et rekombinant DNA-molekyle og et medikament for den specifikke stimulering af serum og sekretoriske antistoffer via mucøs tilstedeværelse af antigener DK171846B1 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
AUPH056685 1985-05-15
AUPH056685 1985-05-15
AUPH310485 1985-10-25
AUPH310485 1985-10-25
AU8600135 1986-05-14
PCT/AU1986/000135 WO1986006635A1 (en) 1985-05-15 1986-05-14 Oral vaccines

Publications (3)

Publication Number Publication Date
DK16487D0 DK16487D0 (da) 1987-01-14
DK16487A true DK16487A (da) 1987-03-16
DK171846B1 DK171846B1 (da) 1997-06-30

Family

ID=25642944

Family Applications (1)

Application Number Title Priority Date Filing Date
DK016487A DK171846B1 (da) 1985-05-15 1987-01-14 Et kompleks, en fremgangsmåde til fremstilling af dette kompleks, en transformant vært, et rekombinant DNA-molekyle og et medikament for den specifikke stimulering af serum og sekretoriske antistoffer via mucøs tilstedeværelse af antigener

Country Status (12)

Country Link
EP (1) EP0222835B2 (da)
JP (1) JP2761849B2 (da)
CN (1) CN86103835A (da)
CA (1) CA1340555C (da)
DE (1) DE3650082T3 (da)
DK (1) DK171846B1 (da)
ES (1) ES8900006A1 (da)
FI (1) FI870140A (da)
HK (1) HK29896A (da)
IL (1) IL78775A (da)
NZ (1) NZ216162A (da)
WO (1) WO1986006635A1 (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8601940D0 (sv) * 1986-04-25 1986-04-25 Kabigen Ab Preparation of fused proteins, antibodies and processes therefor
US4822611A (en) * 1986-12-09 1989-04-18 Immunotec, Inc. Oral hyposensitization in the treatment of allergies
US5112749A (en) * 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
US5135918A (en) * 1988-03-21 1992-08-04 Broncorp Method for decreasing reaginic antibody levels
IL91462A0 (en) * 1988-08-30 1990-04-29 Applied Research Systems Recombinant fusion proteins and dna encoding for such a protein
EP0433372B1 (en) * 1988-09-06 2002-06-12 Washington University Oral immunization by transgenic plants
US6043057A (en) * 1988-09-16 2000-03-28 Vitec Aktiebolag Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
FR2636842B1 (fr) * 1988-09-27 1994-06-10 Liege Universite Etat Proteine de fusion d'une sequence derivee de la sous-unite b de la toxine cholerique et d'un antigene heterologue doue de proprietes immunogenes, compositions de vaccins les contenant et acides nucleiques recombinants contenant une sequence de nucleotides codant pour ladite proteine de fusion
IL92578A0 (en) * 1988-12-07 1990-08-31 Univ Leicester Heat-labile toxin b subunit fusion proteins and their preparation
AU5088690A (en) * 1989-01-06 1990-08-01 Regents Of The University Of California, The Keratoconjunctivitis cytotoxin and methods for its use and production
US6413523B1 (en) * 1989-06-02 2002-07-02 The United States Of America As Represented By The Secretary Of The Navy Pharmaceutical composition of escherichia coli heat-labile enterotoxin adjuvant and methods of use
EP0418626B1 (en) * 1989-09-08 1993-12-29 Takeda Chemical Industries, Ltd. Fused proteins and production thereof
US5032405A (en) * 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
US5378815A (en) * 1989-10-20 1995-01-03 National Research Council Canada Process for indirect targeted immunocytolysis
CA2050425A1 (en) * 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB
CA2098598A1 (en) * 1990-12-21 1992-06-22 Howard C. Krivan Adhesin-oligosaccharide conjugate vaccine for haemophilus influenzae
US5843463A (en) * 1990-12-21 1998-12-01 Antexbiologics, Inc. Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae
DK0501882T3 (da) * 1991-03-01 2000-12-11 Merial Sas Fremgangsmåde til anti-LHRH immunoneutralisering af ikke-kastrerede husdyrhanner og peptider dertil
US6159502A (en) * 1991-04-02 2000-12-12 Biotech Australia Pty Ltd Oral delivery systems for microparticles
GB9112553D0 (en) * 1991-06-11 1991-07-31 Wellcome Found Fusion proteins
ZA934199B (en) * 1992-06-18 1994-01-10 Akzo Nv Carrier system against gnrh
CA2086631C (en) * 1992-12-22 1998-10-06 J. Gabriel Michael Oral administration of immunologically active biomolecules and other therapeutic proteins
US5681571A (en) * 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
DK0805628T3 (da) * 1995-01-17 2003-07-14 Brigham & Womens Hospital Receptor specifik transepitheltransport af immunogener
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
WO1997005267A2 (en) * 1995-07-26 1997-02-13 Maxim Pharmaceuticals Mucosal delivery of polynucleotides
DE19534579C2 (de) * 1995-09-18 2000-06-08 Max Planck Gesellschaft Nucleinsäure-Moleküle codierend Proteine, die die Adhäsion von Neisseria-Zellen an humane Zellen vermitteln
CA2252438C (en) 1996-04-19 2011-03-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
ATE331798T1 (de) 1996-04-19 2006-07-15 Jackson H M Found Military Med Verfahren zur anregung einer immunantwort durch verabreichung von nutzorganismen, die intimin allein oder als fusionsprotein mit einem oder mehreren anderen antigenen exprimieren
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
KR20010043441A (ko) 1998-05-08 2001-05-25 더 유니버시티 오브 브리스톨 백신용 면역조절제
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
ES2233284T3 (es) 1999-02-17 2005-06-16 Pfizer Products Inc. Proteinas de fusion que comprenden portadores que pueden inducir una bdoble respuesta inmune.
FR2791895B1 (fr) * 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
AU784657B2 (en) * 1999-10-22 2006-05-18 Genentech Inc. Delivery of proteins across polar epithelial cell layers
JP5072159B2 (ja) * 1999-10-26 2012-11-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 粘膜アジュバントとしての植物レクチン
US6863896B1 (en) 1999-10-26 2005-03-08 Chiron Corporation Plant lectins as mucosal adjuvants
JP2001335510A (ja) * 2000-05-23 2001-12-04 Masanori Baba エイズワクチン
CA2517439C (en) 2003-03-07 2013-07-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
ATE548657T1 (de) * 2004-07-20 2012-03-15 Symphogen As Prozedur zur strukturellen charakterisierung rekombinanter polyclonaler proteine oder einer polyclonalen zelllinie
JP2008515808A (ja) 2004-10-04 2008-05-15 トリニティ バイオシステムズ インコーポレーテッド 針不用の高分子送達のための方法及び組成物
WO2007042169A2 (en) * 2005-10-07 2007-04-19 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Matrix metalloproteinase 11 vaccine
US7666991B2 (en) 2005-12-05 2010-02-23 Trinity Biosystems, Inc. Compositions for needleless delivery of antibodies
CN106237316A (zh) 2006-03-07 2016-12-21 法克斯因内特公司 包含血细胞凝集素的组合物、制造其的方法与使用其的方法
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
BRPI1015567A2 (pt) 2009-06-22 2021-08-31 Wyeth Llc Composições imunogênicas de antígenos de staphylococcus aureus
NZ597191A (en) 2009-06-22 2013-11-29 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
CN101921726B (zh) * 2010-07-27 2012-08-22 浙江大学 一种口服免疫阻断鸡抑制素作用的转化子及其应用
CN102178699B (zh) * 2011-04-20 2013-03-20 威海康博尔生物药业有限公司 一种用于增强人体免疫力、促进生长发育的制剂
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
WO2017066134A1 (en) 2015-10-16 2017-04-20 Merck Sharp & Dohme Corp. Processes for preparing formulations for gastrointestinal-targeted therapies

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2547224A1 (de) * 1974-11-01 1976-05-13 Sandoz Ag Organische verbindungen, ihre verwendung und herstellung
FR2306684A1 (fr) * 1975-04-11 1976-11-05 Crinex Lab Nouvelle composition a action immunostimulante
GB1553664A (en) * 1975-06-12 1979-09-26 Unilever Ltd Antigenic compositions
ZA802992B (en) * 1979-06-01 1981-10-28 Univ California Human pre-growth hormone
JPS5639022A (en) * 1979-09-05 1981-04-14 Hayashibara Biochem Lab Inc Preparation of vaccine
CA1198385A (en) * 1980-03-17 1985-12-24 Leonard P. Guarente Optimal polypeptide production
EP0049945A3 (en) * 1980-09-15 1982-12-01 Bactex Incorporated Determining a hierarchy of piliated organisms and a vaccine prepared from such organisms
GB2094314A (en) * 1981-02-05 1982-09-15 Wellcome Found Recombinant DNA
WO1982003088A1 (en) * 1981-03-09 1982-09-16 Corp Cetus Vaccines
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
DE3369466D1 (en) * 1982-05-12 1987-03-05 Harvard College Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
DE3382547D1 (de) * 1983-01-12 1992-05-27 Chiron Corp Sekretorische expression in eukaryoten.
DK219084D0 (da) * 1984-05-02 1984-05-02 Frederik Carl Peter Lindberg Antigen
EP0177583A4 (en) * 1984-04-06 1988-06-08 Scripps Clinic Res PEPTIDE VACCINE OR DIAGNOSTIC, AND POLYPEPTIDE FOR USE THEREOF.
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
ATE78515T1 (de) * 1984-10-05 1992-08-15 Genentech Inc Dna, zellkulturen und verfahren zur sekretion von heterologen proteinen und periplasmische proteinrueckgewinnung.
NZ213759A (en) * 1984-10-19 1989-01-27 Genentech Inc Lhrh-ctp protein conjugates influencing prolactin fsh and lh release
US4556555A (en) * 1985-01-25 1985-12-03 North Carolina State University Process for the immunological neutering of animals

Also Published As

Publication number Publication date
CA1340555C (en) 1999-05-25
EP0222835B2 (en) 2000-04-19
AU5861286A (en) 1986-12-04
DK16487D0 (da) 1987-01-14
ES8900006A1 (es) 1988-10-16
EP0222835A4 (en) 1988-02-01
NZ216162A (en) 1989-04-26
JP2761849B2 (ja) 1998-06-04
HK29896A (en) 1996-02-23
IL78775A0 (en) 1986-08-31
DK171846B1 (da) 1997-06-30
EP0222835B1 (en) 1994-09-28
CN86103835A (zh) 1987-04-08
ES554969A0 (es) 1988-10-16
DE3650082T3 (de) 2000-12-21
DE3650082T2 (de) 1995-05-04
JPH07213290A (ja) 1995-08-15
IL78775A (en) 1992-06-21
DE3650082D1 (de) 1994-11-03
WO1986006635A1 (en) 1986-11-20
EP0222835A1 (en) 1987-05-27
FI870140A0 (fi) 1987-01-14
FI870140A (fi) 1987-01-14
AU594059B2 (en) 1990-03-01

Similar Documents

Publication Publication Date Title
DK16487A (da) Vacciner til oral indgift
NO175620C (no) Fremgangsmåte for fremstilling av et antitumorvirksomt legemiddel
IT7905216A0 (it) Soluzione di amminoacidi per pazienti affetti da carcinoma.
DK0548114T5 (da) Mometason-furoat-monohydrat, fremgangsmåde til fremtilling deraf og farmaceutiske præparater indeholdende dette
NO833769L (no) Immunogent protein- eller peptidkompleks, fremgangsmaate for fremstilling og anvendelse herav som immunstimulerende middel og som vaksine
DE60038104D1 (de) Arzneimittelzubereitungen für die behandlung von alpha-galactosidase a-mangel
IT8948599A0 (it) Procedimento per eliminare composti gassosi contaminanti, in particolare di droganti da gas vettori contenenti composti di alogenosilano
NL7507268A (nl) Werkwijze ter bereiding van 1(alpha),24-dihydroxy-chole- calciferolen, alsmede derivaten en voorlopers daar- van , alsmede farmaceutische preparaten die deze ver- bindingen als actieve componenten bevatten.
IT1140521B (it) Sistema medicinale da somministrare per via intradermica per dinitrato di isosorbite
DK0526524T3 (da) Farmaceutiske præparater
DE69422712D1 (de) Tris-platin-komplexe
DE69812100D1 (de) Adenosin enthaltendes arzneimittel
DK0521057T3 (da) Farmaceutiske midler indeholdende ipriflavon, fremgangsmåde til fremstilling deraf, og relativ terapeutisk anvendelse
BR9807332A (pt) Antìgenos de leishmania para utilização na terapia e diagnóstico de leishmaniose
DK52080A (da) Dehydropeptider fremgangsmaader til deres fremstilling samt deres anvendelse som laegemidler
DK463283A (da) Glycosidbinding-relateret antigen, fremgangsmaade til fremstilling heraf og anticancermiddel indeholdende dette antigen som aktiv komponent
ES2037003T3 (es) Procedimiento para preparar peptidos empleando percloratos.
NL7606043A (nl) Werkwijze ter bereiding van farmaceutische pre- paraten, alsmede werkwijze ter bereiding van nieuwe aminederivaten.
FI890864A (fi) Anvaendning av 1,4-dihydropyridinderivat.
ATE137487T1 (de) Komplexe, enthaltend s(+)-phenyl-alkansäuren und alpha-hydroxy-alkansäuren
IT8021160A0 (it) Apparecchio per la somministrazione di gas.
SU861004A1 (ru) Устройство дл ориентации плоских деталей
PH13837A (en) Influenza vaccine containing purified neuraminidase antigen and method of using the same
JPS51123834A (en) A medicine against the headache
DK381787A (da) Rensede antigener med vaccineegenskaber mod b. pertussis, midler, navnlig rekombinant-dna, til fremstilling deraf og vaccinepraeparater indeholdende disse

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment
B1 Patent granted (law 1993)
PBP Patent lapsed